Cipla USA Initiates Nationwide Class III Recall of Albuterol Sulfate Inhalation Aerosol Due to Stability Failures
Cipla USA, Inc. has initiated a U.S. nationwide Class III recall for 20352 packs of Albuterol Sulfate Inhalation Aerosol (NDC 69097-142-60). The recall, D-0593-2025, stems from failed stability specifications, specifically out-of-specification particle size distribution at the 12-month time point. This event necessitates immediate supply chain assessment and robust quality oversight for procurement and regulatory teams.
FDA Initiates Class III Recall for Cipla USA's Albuterol Sulfate Inhalation Aerosol
Cipla USA, Inc. has initiated a voluntary Class III recall for 20352 packs of Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 metered inhalations, distributed nationwide across the U.S. This action, identified as recall number D-0593-2025, was initiated on July 24, 2025, following the detection of out-of-specification (OOS) results during stability testing. Specifically, the product, from Lot#: 4IB0519 with an expiration date of April 30, 2026, failed particle size distribution specifications at the 12-month stability time point, with issues observed in the Induction Port. This recall underscores the critical importance of maintaining product quality throughout its shelf life, particularly for inhalation products where precise particle size is paramount for efficacy and patient safety. For procurement directors and supply chain VPs, this event signals an immediate need to assess inventory levels of Albuterol Sulfate from Cipla USA, Inc. and identify potential short-term supply disruptions. The nationwide distribution pattern means that the impact could be widespread, necessitating rapid communication with distributors and healthcare providers. Regulatory affairs heads must ensure their internal quality systems align with FDA expectations for stability monitoring and recall procedures, especially when dealing with products manufactured by third parties, as this product was manufactured by Cipla Ltd in India for Cipla USA, Inc. Business development executives should evaluate the competitive landscape for respiratory generics, as such recalls can create opportunities for alternative suppliers to gain market share.
Manufacturing Quality Breach: Particle Size Distribution Failure in Albuterol Sulfate
The core issue leading to Cipla USA, Inc.'s recall of Albuterol Sulfate Inhalation Aerosol is a failure in stability specifications, specifically concerning particle size distribution at the 12-month time point. Out-of-specification results were observed in the Induction Port, a critical component for delivering the metered dose effectively. For an inhalation aerosol like Albuterol Sulfate, which is crucial for managing conditions such as asthma and COPD, the particle size distribution directly impacts drug delivery to the lungs, bioavailability, and ultimately, therapeutic efficacy. Deviations from the specified particle size can lead to suboptimal drug deposition, reducing the intended therapeutic effect and potentially compromising patient health, even if the FDA classified this as a Class III recall, indicating a remote probability of serious adverse health consequences. This incident highlights a significant quality control challenge originating from the manufacturing site, Cipla Ltd, Indore, SEZ, Pithampur, India, which produced the affected Lot#: 4IB0519. Procurement and regulatory teams must scrutinize their supplier qualification processes, particularly for contract manufacturers located in international geographies. Ensuring robust quality agreements, rigorous audit programs, and continuous monitoring of critical quality attributes like particle size distribution are non-negotiable. The failure at the 12-month mark emphasizes the necessity of comprehensive, long-term stability studies that accurately predict product performance throughout its entire shelf life. For business development, this reinforces the value of suppliers with impeccable quality records and transparent manufacturing processes, reducing the risk of costly recalls and reputational damage.
Market Impact and Supply Chain Considerations for Generic Albuterol Sulfate
The U.S. Nationwide distribution of 20352 packs of Cipla USA, Inc.'s Albuterol Sulfate Inhalation Aerosol (NDC 69097-142-60) means that the recall, initiated on July 24, 2025, has broad implications for the domestic pharmaceutical supply chain. While classified as a Class III recall, suggesting a remote probability of serious adverse health consequences, the sheer volume and widespread distribution of a commonly used respiratory medication cannot be overlooked. Procurement directors must immediately assess their current stock of the affected Lot#: 4IB0519 and initiate quarantine and return procedures. The recall of a generic drug like Albuterol Sulfate, which often serves as a cost-effective and readily available treatment option, can lead to localized supply gaps, particularly if alternative suppliers cannot quickly scale up production or if healthcare providers face delays in switching to different brands or generics. Supply chain VPs need to activate contingency plans, identifying and qualifying alternative sources for Albuterol Sulfate to mitigate potential shortages and ensure continuity of patient care. This situation underscores the vulnerability of single-source or concentrated supply chains for essential medicines. Regulatory affairs heads should review their post-market surveillance and recall management protocols to ensure swift and compliant execution. Business development executives should monitor market shifts, as competitors with robust quality systems and available inventory may capitalize on this disruption. The incident also puts pressure on Cipla USA, Inc. to demonstrate effective recall management and transparent communication to maintain trust with its customers and the regulatory body.
Broader Regulatory Environment and Industry Vigilance Post-Recall
The voluntary recall of Albuterol Sulfate by Cipla USA, Inc. occurs within an increasingly stringent global regulatory landscape, where the FDA maintains high vigilance over pharmaceutical quality and manufacturing compliance. While this specific event is a Class III recall, it aligns with a broader industry trend of heightened scrutiny. For instance, recent parallel events include FDA's Class II recall of Essential Wellness Pharma's Progesterone Injection due to sterility assurance failures in June 2026, and an FDA hearing in June 2026 that placed Amgen's Tavneos market future at risk following an independent data review. These incidents, though distinct in nature and severity, collectively signal the FDA's unwavering commitment to product safety and efficacy, irrespective of the product's therapeutic area or market position. For senior decision-makers, these ongoing regulatory actions emphasize that robust Quality Management Systems (QMS) are not merely a compliance checkbox but a fundamental business imperative. Procurement directors must prioritize suppliers with demonstrated, consistent adherence to cGMP standards, understanding that a lapse by any supplier can trigger significant supply chain disruptions and reputational damage. Regulatory affairs heads should proactively monitor FDA guidance and enforcement trends, ensuring internal processes anticipate and mitigate potential compliance risks. Business development executives must factor regulatory risk into their market entry and partnership strategies, favoring entities with strong compliance track records to safeguard long-term commercial viability and patient trust.
Cipla USA's Remediation Path and Future Compliance Expectations
Following the voluntary recall of Albuterol Sulfate Inhalation Aerosol, Cipla USA, Inc. is now obligated to conduct a thorough root cause analysis to identify precisely why the particle size distribution failed stability specifications at the 12-month mark. This investigation must extend to the manufacturing processes at Cipla Ltd in Indore, India, where the affected Lot#: 4IB0519 was produced. The FDA will expect comprehensive corrective and preventive actions (CAPA) to be implemented, addressing not only the immediate product failure but also systemic issues that could lead to similar problems in other products or batches. This could involve re-evaluating raw material specifications, optimizing manufacturing parameters, enhancing in-process controls, or revising stability testing protocols. For procurement directors, this situation underscores the critical need for ongoing supplier performance monitoring, extending beyond initial qualification. Regular audits, performance metrics, and transparent communication channels with manufacturers like Cipla Ltd are essential to proactively identify and address quality deviations. Regulatory affairs heads must ensure that Cipla USA, Inc.'s CAPA plan is robust, adequately documented, and effectively implemented to prevent recurrence, as future non-compliance could lead to more severe regulatory actions, including potential import alerts for the manufacturing facility. Business development executives should recognize that a swift and effective remediation strategy is vital for restoring market confidence and protecting Cipla's brand reputation in the competitive U.S. generics market. The successful resolution of this recall will be a key indicator of Cipla's commitment to quality and regulatory compliance.